Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:CPRX 15 December 2025 - 30 December 2025

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals confirmed CEO Rich Daly will present at the J.P. Morgan Healthcare Conference on January 12, 2026. CPRX traded near $23.95 Monday, below the $26.58 technical level watched by traders. Shares saw volume around 822,000 and a Relative Strength Rating increase from 61 to 73. Analysts cited ongoing debate over the stock’s next move after a strong year.
15 December 2025
·

Stock Market Today

  • TD1.AX TALi Digital plunges 16.67% amid liquidity concerns and sector weakness
    March 20, 2026, 11:34 PM EDT. TD1.AX shares of TALi Digital Limited fell 16.67% intraday to A$0.04 on March 21, 2026, marking significant losses for the small-cap healthcare tech stock. Trading volume hit 67,918 shares, below average, highlighting limited liquidity and sharp price swings. The company's earnings report shows ongoing losses with an EPS of -0.02 and weak revenue growth, intensifying investor concerns amid a pressured ASX healthcare sector. Financial ratios indicate a stable liquidity cushion but stretched receivables and negative free cash flow point to operational risks. Technical indicators reveal the stock is oversold, with forecasts suggesting potential upside of up to 66% over 12 months, though risks persist given thin trading and negative margins.
Go toTop